MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS - from the same manufacturing donor batch, without genetic engineering Findings underscore the intrinsic biology of iNKT cells and the manufacturing scale for a broadly deployable cell therapy capable of expansion in multiple disease indications without disease-specific engineering Clinical activity in both settings: tumor responses including complete metastatic remission in oncology; improved survival and pathogen clearance in severe ARDS Data support advancement into a randomized Phase 2 trial in acute lung injury (C-1300-02); preliminary data expected in 2026 NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.